This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
9 Oct 2011

FDA Approves ANDA of Loxapine Capsules

Lannett Company has received approval from the FDA for its Loxapine Capsules in 5mg, 10mg, 25mg and 50mg doses.

The US FDA has approved Lannett's abbreviated new drug application (ANDA) of Loxapine Capsules in 5mg, 10mg, 25mg and 50mg doses. Lannett expects to start commercialising the product in the next few weeks.

 

Loxapine Capsules are therapeutically equivalent to Watson Pharmaceuticals' Loxitane Capsules.

 

Lannett president and CEO Arthur Bedrosian said they have now received five product approvals from the FDA over the last three months.

Related News